Myopia Prevalence by Study Population:
21 Global Cohorts with Risk Factor Data

Peer-reviewed prevalence rates, primary risk factors, and documented interventions across 21 study populations worldwide. Data from 6 published sources including the IMI 2021 Digest and NIH/PMC epidemiological reviews.

94.9%
Highest rate — Tokyo junior high students
3.7%
Lowest rate — Irish schoolchildren aged 6–7
21
Study populations across 14 countries
9.8%
Global high myopia projection by 2050
Region / Country Population Group Prevalence Rate Primary Risk Factors Interventions Documented
East Asia
China (Metropolitan)
15-year-olds 78.1% Academic demands, screen exposure >3 hrs/day, reduced outdoor time
East Asia
Taiwan
High schoolers 84% Near-work activities, educational pressure 'Tian-Tian 120' — 120 min/day outdoor time in schools
East Asia
South Korea
Young adults 90% Intensive educational frameworks, rapid urbanization, lifestyle shifts
East Asia
Japan (Tokyo)
Students aged 6–14 76.5% (primary) → 94.9% (junior high) Educational institutions, lifestyle (environmental)
East Asia
Korea
Children aged 5–18 64.6% Parental myopia, female gender
East Asia
China (Guangzhou)
1st-grade children 39.5% control vs 30.4% intervention (3-yr cumulative) Insufficient time outdoors Outdoor time intervention (school-based)
East Asia
China (East)
Third-year high school (mean age 18.4) 79.5% (2001) → 87.7% (2015) Female gender
East Asia
China (East)
Children aged 5–20 (mean age 12.3) 63.1% Moderate to high school workload, female gender
East Asia
China (Hong Kong)
Children
SE Asia
Singapore
12-year-olds 65% Education intensity, urban environments National Myopia Prevention Program (NMPP), school-based screenings
SE Asia
Vietnam
Secondary students 56.3% Urbanization, self-study >2 hrs/day, extra classes
South Asia
India (North)
Schoolchildren aged 5–15 21.1% Low outdoor activity (<1.5 hrs/day), reading/writing >4 hrs/day, video games >2 hrs/day
North America
United States
Adults (20+) 36.2% Lifestyle, ancestry-linked susceptibility
North America
United States
Children aged 6–11 Accommodative lag, near esophoria
North America
Mexico
Outpatients 44.4% Astigmatism identified as major risk factor
North America
Canada
11–13 year-olds 28.9%
Europe
Norway
Adolescents aged 16–19 13.4% Less sport/outdoor time
Europe
Ireland
Schoolchildren aged 6–7 and 12–13 3.7% → 22.8% (by age) Paternal myopia, screen use >3 hrs/day, frequent reading, high BMI
Middle East
Israel
5-year-olds (post-COVID) 12.6% COVID-19 lockdowns, increased screen time, reduced outdoor activity
Global
Multi-centre
Children
Global
2050 Projection
General population 9.8% (high myopia) Urbanization, axial elongation

Key Patterns Across Populations

East Asia leads globally — rates of 60–94% in adolescent populations, driven by high academic intensity, near-work load, and reduced outdoor time. Taiwan's 'Tian-Tian 120' policy (mandatory 120 min/day outdoor time in schools) represents the most documented population-level intervention, associated with the Guangzhou RCT showing a 9.1 percentage-point reduction in cumulative 3-year myopia incidence.

Europe and North America show a wide spread — from 3.7% in young Irish children to 44.4% in Mexican outpatients. Risk factors in these regions emphasize screen use, paternal myopia, and reading habits rather than systemic academic pressure.

The COVID-19 effect is documented — Israel shows 12.6% in 5-year-olds post-COVID, attributed to lockdown-driven increases in screen time and reduction of outdoor activity. This cohort (aged 5–9 in 2020) is now 11–15 and in clinical practice.

Plot your patient against global norms

Enter age + axial length to see where your patient sits vs age-matched normative data. Free, no login.

Open Calculator →

Sources: [1] The Global Myopia Pandemic — Comprehensive Epidemiological Analysis (multiple regions) · [2] High myopia and its risks — PMC/NIH · [3] Onset and Progression of Myopia — NCBI Bookshelf · [4] Recent Epidemiology Study Data of Myopia — PMC/NIH · [5] Myopia — StatPearls/NCBI · [6] IMI 2021 Reports and Digest — PMC · Rows with no prevalence data reflect populations where study design focused on risk factor identification rather than prevalence estimation.